Stay updated on Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial page.

Latest updates to the Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThis updates the website’s displayed revision/version number from v3.5.0 to v3.5.3, reflecting a documentation or platform release rather than any change to the clinical trial content.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedAdded posted results data including incidence of dose-limiting toxicities, 18-month overall survival, and adverse events with time-to-event endpoints, and updated results reporting dates. Linked or updated study documents (protocol/consent forms) accompany the results.SummaryDifference2%

- Check44 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check59 days agoChange DetectedAdded Revision: v3.4.3 and removed Revision: v3.4.2.SummaryDifference0.0%

- Check80 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no substantive content changes are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check88 days agoChange DetectedThe change consists only of a version revision tag, updating from v3.4.0 to v3.4.1, with no changes to study content or page functionality. To avoid being alert by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial page.